Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX110 via CED in recurrent glioblastoma
NCT05324501Phase 1Terminated
- Sponsor
- Biodexa Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of MTX110 in glioblastoma (GBM) (2 cohorts), sponsored by Biodexa Pharmaceuticals. Primary endpoints: Safety of MTX110 administered by CED at 28 weeks and Recommended Phase 2 Dose at 28 weeks. Started Oct 2022; status: terminated.
02
Drugs
MTX110
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05324501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05324501.